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Malignant salivary gland tumors (MSGTs) account for 2–6% of all head and neck cancers. Despite the rarity, MSGTs have been of
great interest due to a wide variety of pathological features and high metastasis rates resulting in poor prognosis. Surgical resection
followed by radiation therapy represents the main treatment of this malignancy. Adjuvant therapy is reserved for the management
of local recurrence, no longer amenable to additional local therapy, and for metastasis. Based on the studies from other types of
tumors, particularly breast cancer, the expression and function of sex steroid hormone receptors in cancer have been extensively
studied and applied to diagnosis and treatment. Although a number of studies in MSGTs have been published, the rationale for
hormone therapy is still controversial due to the disparate results and insuﬃcient number of cases. However, some recent reports
have demonstrated that certain salivary gland neoplasms are similar to breast cancer, not only in terms of the pathological features,
but also at the molecular level. Here, we shed light on the biological similarity between MSGTs and certain types of breast cancer,
and describe the potential use of hormone and additional therapies for MSGTs.
1. TheRoleofSexSteroidHormoneReceptorsin
Cancer Therapy
The function of sex steroid hormone receptors in breast
cancer has been extensively studied and applied to diagnosis
and treatment [1, 2]. Estrogen stimulates cell proliferation of
breast epithelial cells, and the close relationship between the
expression of estrogen receptor (ER) and the prognosis of
breast cancer has been well characterized [3]. Progesterone
levels ﬂuctuate during the menstrual cycle and regulate cell
proliferation and diﬀerentiation; however, less is known
regarding its role in breast cancer [4–6]. We have previ-
ously identiﬁed that introducing progesterone receptor (PR)
into hormone-independent breast cancer cells signiﬁcantly
suppressed their proliferative and invasive activities upon
progesterone treatment [7].
Several drugs such as Tamoxifen, an estrogen receptor
antagonist, as well as a synthetic progestin similar to pro-
gesterone, are considered to be eﬀective at inhibiting tumor
cell proliferation. These drugs are given as adjuvant therapies
in breast cancer patients when greater than 10% of the
breast cancer cells express ER or PR receptors as assessed
by immunohistochemical staining of the tumor tissue [8, 9].
Molecular targeted drug therapy is generally deﬁned as less
toxic than traditional chemotherapy; however, some studies
have reported severe side eﬀects, and carefully designed and
regulated clinical trials are necessary to conﬁrm the safety.
Moreover, these types of therapies are not viable when a
tumor expresses a low level of a molecular target, for exam-
p l e ,ar e c e p t o r[ 10]. This problem is exempliﬁed in breast
cancers which do not express ER, PR, or HER2 receptors,
that is, triple negative cases. In this patient population, it is a
challenge for clinicians to provide eﬃcacious treatments.
Sex steroid hormone therapy in prostate cancers is based
on their high sensitivity to androgen inhibition. The most
common hormone therapy is initiated by reducing the
concentration of circulating androgens through surgical or
medical castration and/or by administering antiandrogens2 International Journal of Otolaryngology
such as ﬂutamide or bicalutamide [11, 12]. However, in
almost all patients, the eﬃcacy of the treatment decreases
over time as the tumor becomes “androgen refractory” [13].
As a result, these patients develop distant metastases, such as
in bone, which eventually is fatal to the patient. The molec-
ular events, therefore, which control the transition from
androgen-sensitive prostate cancer to androgen-refractory
prostate cancer need to be elucidated.
Accumulatingevidencesuggeststhattheandrogenrecep-
tor (AR) plays a critical role in regulating the growth of both
androgen-sensitive and androgen-refractory prostate cancer
[14–19]. In addition, recent studies showed that the AR can
regulate invasion and metastasis [20]. In AR-negative cell
lines such as PC3 and DU145, it has been shown that forced
AR expression decreased invasive properties and treatment
with androgen further reduced invasion of these cells [21,
22]. Moreover, it was reported that hormone refractory
prostate cancers demonstrated a variety of AR alterations
that were either not found in hormone na¨ ıve tumors or
found at lower frequency [19] .Am o r er e c e n ti n v e s t i g a t i o n
has demonstrated that forced expression of AR, in a subline
of a metastatic androgen-dependent prostate cancer cell line,
led to increased invasion [20]. It is clear that a more detailed
understanding of the AR alterations in the evolution of
androgen-refractory prostate cancer is needed to help drive
the development of potential new therapies.
Regarding the potential applications of hormone thera-
pies against other cancers, some studies in ovarian and colon
cancer have been described [23]. In ovarian cancer, the use
of estrogen as a menopausal therapy has frequently been
associated with an increased risk of ovarian cancer, and there
is still conﬂicting evidence on the impact hormone therapy
has on decreasing the risk of cancer [24]. A recent study,
however, suggests that this problem can be circumvented
by coadministering progestin and estrogen [25]. Further,
experiments in culture showed that progesterone reduced
proliferation of both benign and malignant ovarian tumor
cells [26]. Therefore, progestin might be a key factor to
prevent and suppress ovarian cancer cell growth. In contrast
to ovarian cancer, estrogen appears to have protective eﬀects
against colon cancer [27]. However, the role of hormone
replacement therapy involving estrogen for treatment of
colon cancer is poorly understood, and further analyses are
needed.
2.Pathological andBiological Similarities
betweenMSGTs andBreast Cancer
Mammary and salivary glands are tubuloacinar exocrine
glands and share similar morphological characteristics.
Comparing the tumors arising from these two diﬀerent sites,
similar histological features are observed [28–31]. Although
the cancers diﬀer in incidence and clinical behavior, certain
biological features identiﬁed in both entities have been
described, and potential common therapeutic approaches
have been considered.
The WHO classiﬁcation of MSGTs represents more than
twenty diﬀerent histological subtypes [32, 33]. The majority
of them are divided into two groups, the secretory duct
origin (including mucoepidermoid carcinoma (MEC) and
salivary duct carcinoma (SDC)) and the intercalated origin
type (including adenoid cystic carcinoma (ACC)) [34, 35].
Most of these tumors occur in the parotid gland (70%), and
less than 25% are malignant [36]. Although the incidence
of tumors at other sites, such as submandibular, sublingual,
and minor salivary glands, is less common, the proportion
of malignancy is higher, approximating 50% [36]. Most of
aggressive breast cancers are composed of invasive ductal
carcinoma, and other histologic features such as MEC and
ACC are relatively rare. Below, we brieﬂy describe some
of the types of MSGTs that display common features (at
the morphological and molecular levels) with breast cancers
and, therefore, could provide potential common therapeutic
strategies.
2.1. Mucoepidermoid Carcinoma (MEC). MEC is the most
common salivary gland neoplasm, accounting for 29–34%
of all malignancies of the major and minor salivary glands
[32]. These tumors grow slowly and present painless massed
in most cases. They are primarily composed of intermediate,
mucous, and epidermoid cells. The cell types are classiﬁed
histologically as low, intermediate, and high grade, and 5-
year overall survival (OS) varies from 92% to 100% in low-
grade tumors, 62% to 92% in intermediate-grade tumors,
and 0% to 43% in high-grade tumors [37]. High-grade MEC
is an aggressive malignancy, characterized by high rate of
localrecurrenceanddistantmetastasis.Onthecontrary,low-
grade MEC generally do not metastasize.
On the other hand, MEC of breast is a rare entity with an
estimated incidence of 0.2% and is composed of a mixture
of basaloid, intermediate, epidermoid, and mucinous cells
[30, 38]. Since Patchefsky et al. ﬁrst described breast MEC
in 1979, only 28 cases have been reported [38–53]. Because
of the rarity, the prognosis is still controversial. However, it
was described that MECs deriving from breast and salivary
glands share similar biological features and morphologies
[30]. They classiﬁed breast MECs into three grades using the
same grading system as for the salivary gland tumors and
demonstrated that high-grade tumors show high mortality
resulting from lymph node and distant metastasis. These
results suggest that MECs from both mammary and salivary
glands, having similar morphological features, could have
similar treatment strategies.
Further, a common cytogenetic alteration of breast and
salivary MECs has been reported. A reciprocal translocation
t(11;19)(q21;p13) (MAML2:MECT) was shown in breast
MEC, whichis known as the most frequentgenetic alteration
ofsalivaryglandcounterparts[54].Thistranslocationcreates
a fusion product (MAML2:MECT1) that activates transcrip-
tion of cAMP/CREB target genes [54, 55]. Another report
described that the expression of the protein fusion gene was
associated with a signiﬁcantly lower risk of death compared
to those without the fusion protein MAML2:MECT1 [56].
It has also been shown that other subtypes of breast cancers
are negative for this gene, suggesting that this fusion gene is
speciﬁctoMEC.Thistranslocationislikelytobeapromising
marker for MECs from both breast and salivary gland [57].International Journal of Otolaryngology 3
2.2. Adenoid Cystic Carcinoma (ACC). ACCs account for
22% of MSGTs [58]. There are three histological subtypes:
tubular, cribriform, and solid [29, 59]. In contrast to squa-
mous cell carcinomas that account for the vast majority of
head and neck malignancies, ACC often spreads systemically,
especially to lung and bone, and the metastatic proportion
of this type of neoplasm represents 24–55% [60]. Due to the
highmetastaticrate,prognosisispoor.The10-yearOSis39–
55%, and 20-year OS is 21–25% [60].
On the other hand, breast ACC is a rare malignancy,
accounting for 0.1–1% of all breast cancers [31]. In addition,
these neoplasms show diﬀerent clinical behaviors than their
salivaryglandcounterparts.10-yearOSrepresentsmorethan
90%, and lymph node and distant metastases are generally
rare [31]. However, the histological features of breast ACCs
are very similar to ACCs originating from salivary glands
(as shown in Figure 1). Ro et al. applied the same grading
system to ACCs from both types of tissues, and breast
and salivary gland tumors are characterized by expression
of c-KIT and share a common chromosomal translocation
t(6;9) leading to the fusion gene MYB-NFIB [31, 61, 62].
c-KIT has been shown to be expressed in 80–100% of
ACCs of salivary gland and in almost all ACCs from the
breast [63–70]. The genetic alteration t(6;9)(q22-23;p23-
24) was ﬁrst identiﬁed as a characteristic for salivary gland
ACCs [71]. Since then, the same translocation has been
detected in breast tumors [62] .T h ef u s i o ng e n ei sh i g h l y
expressed in proliferating cells and is downregulated, as the
cells become more diﬀerentiated. Therefore, this gene may
provide new therapeutic approaches for the management of
ACCs.
2.3. Salivary Duct Carcinoma (SDC). SDC is a rare and
highly aggressive neoplasm representing close histologic
features with invasive ductal carcinoma of the breast (IDC)
[28, 72, 73]. SDC generally shows more aggressive features
and less survival rates than other MSGTs. The epithelium
tendstoformcribriform,papillary,andsolidgrowthpatterns
along with the duct-like structures [28]. The morphology of
SDCischaracterizedbycuboidalandpolygonalcellsforming
distended ducts and solid nests (often with central necrosis)
and which are very similar to comedo carcinomas of the
breast[28].Inadditiontothehistopathologicalresemblance,
both entities have similar clinical behaviors; that is, they have
highly metastatic features leading to poor prognosis.
A wide variety of molecular studies have been performed
and led to the identiﬁcation of certain biological markers
for SDCs. Among them is HER-2, which is ampliﬁed in 20–
25% of breast cancers [74, 75]. Various studies of HER-2 in
SDC have shown variable results, with ampliﬁcation ranging
between 25% and 100% of the tumors [76]. Nonetheless,
the proportion is much higher than in other histological
subtypes such as ACCs and MECs described above [8, 28,
32, 36, 77–84]. HER-2 expression is considered to correlate
with histological grades in both salivary gland neoplasms as
well as breast cancer, and it represents a potential attractive
therapeutic approach for SDCs. As HER-2 can also enhance
AR function, antiandrogen therapy may be eﬀective against
MSGTs when HER-2 is overexpressed.
Previous studies have described that high EGFR expres-
sion in SDCs may contribute to tumor growth [78, 85].
EGFR has been shown to enhance tumorigenesis in several
human carcinomas by blocking apoptosis and promoting
angiogenesis [86]. Regarding both EGFR and HER-2, the
interactionwithhormonalpathwayshasalsobeendescribed.
In the breast and uterus cancers, treatment with anti-EGF
antibodies reduced tumor proliferation induced by treat-
ment with estradiol. Likewise, the antiestrogen ICI 164,384
reduced the eﬀects of EGF-induced tumor proliferation [87].
Hoang et al. performed molecular studies, using micro-
satellite markers and DNA ﬂow cytometry, and compared
the biological characteristics underlying SDC and IDC.
They determined that there were similar allelic alterations
on chromosomal arms 6q, 16q, 17p and 17q, and that
DNA aneuploidy in both malignancies may contribute to
their aggressive behavior [88]. Recently, it was determined
that polysomy of chromosome 7 was detected in 25% of
SDCs and this alteration correlated with poor OS [89].
This correlation was also reported in IDCs and supported
the notion that EGFR gene mutations may guide therapy
[90]. Taken together, gene alterations of both EGFR and
HER-2 may deﬁne molecular features of these two types
of malignancies, and these receptors may be candidates for
targeted therapy.
3. Hormone Therapy for the Treatment of
Patients withMSGTs
As described above, several types of MSGTs are morphologi-
cally and biologically similar to malignant breast cancers [29,
91]( Figure 1). Further, the clinical signiﬁcance of sex hor-
mone receptors has been debated since White and Garcelon
ﬁrst described therapy with estrogen against salivary gland
neoplasms in 1955 [92]. Previous reports obtained using a
lownumberofbiopsysampleshaveshownconﬂictingresults
regarding the expression of sex hormone receptors, making
diﬃcult to determine the potential beneﬁts of hormone
therapy [93–103]. Therefore, additional studies are required
in order to clarify the role of hormone receptors in MSGTs.
AlthoughseveralstudiesexaminedERandPRexpression
in MSGTs, there is substantial disparity in the results: the
expression of ER and PR can vary between 0–86% and 0–
50%, respectively [93–103]. This disparity may be explained
by diﬀerences in antibodies used, experimental methods for
detection (e.g., Western blotting versus immunohistochem-
istry), and the criteria used to rule out false positives and
negatives. It is, therefore, particularly critical to standardize
protocols (such as for the IHC) similar to that described for
the analysis of breast cancer tissues. In addition, some of the
diﬀerences might result from insuﬃcient number of samples
available.
Even though ER expression is unlikely to represent a
useful marker for detecting MSGTs, a subset of MSGTs
clearly expresses hormone receptors, and these receptors
could control disease progression. Thus, current therapeutic
strategies used in breast cancer patients may also be eﬀective
for the treatment of MSGTs. Moreover, the feasibility of
hormonetherapyseemstobesupportedbytheaccumulating4 International Journal of Otolaryngology
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Figure 1:Histologicalcomparisonofmalignantsalivaryandmammaryglandtumors.Salivaryglandsandmammaryglandsarebothtubuloac-
inar exocrine tissues sharing similar morphological features. It is, therefore, expected that the tumors originating from these two diﬀerent
glands would show similarities in their response to hormonal treatment.
reportsofARexpressioninSDCs.Althoughtheexpressionof
AR is generally rare in salivary gland neoplasms, SDCs com-
monly express AR in 92–100% of the cases [85, 104, 105].
Recently, Jaspers et al. reported that androgen deprivation
therapy (ADT) in patients with recurrent or disseminated
disease showed a clinical beneﬁt in ﬁve out of ten cases, and
two of them had partial responses [76]. This approach is,
therefore, more eﬀective than the results obtained after the
use of chemotherapy. Given the fact that ADT has generally
lessadverseeﬀectsthanchemotherapy,antiandrogentherapy
may lead to better clinical outcome and become a standard
treatment method for SDCs.
Williams et al. described that most tumors derived from
breast and salivary glands expressed estrogen receptor-beta
(ER-β) and that the patients whose tumors lacked ER-β were
at higher risk for local recurrence [8]. In addition, previous
studies have linked the loss of ER expression to aggressive
featuresinadenocarcinomasfrombreast,prostate,andcolon
[106–111]. In breast and prostate carcinoma, ER-β has been
shown to inhibit cell proliferation by cyclin D1 pathway and
toinduceapoptosisbydownregulatingbcl-2and/orinducing
Bax expression [112, 113]. Targeting ER-β may, therefore,
become a useful approach for the management of salivary
duct carcinoma.
In our previous studies, we determined that MSGTs cell
lines in culture lacked estrogen and progesterone receptors.
However,lackofhormonereceptorsmaybeaconsequenceof
malignant transformation and may represent a requirement
for the establishment of immortal cell lines. Studies have
reported the eﬃcacy of Tamoxifen against MSGTs in patients
[114, 115], and one of them showed a long-term survival
even though ER was not detected by immunohistochemistry.
This result appears to be supported by another case report,
where Tamoxifen could reactivate ER expression [116]. Our
previous studies showed that progesterone could suppress
MGST cell aggressiveness similarly to that observed in breast
cancer cells (Figure 2). Speciﬁcally, we demonstrated that
after transduction of PR, progesterone could signiﬁcantly
suppress proliferation (and invasion) of MSGT cells [117].
This suppression did not lead to cell death but to cell-cycle
arrest. These data suggest that if MSGTs express signiﬁcant
levels of PR, then progesterone treatment may slow the
growth of the primary tumor and potentially shift it to a
dormantstate.SincemostMSGTsoccurinolderagepatients,
triggering tumor dormancy could improve quality of life
and may be a successful way to allow the patient a normal
lifespan.
Although 5-year OS in patients with MSGTs represents
the average, extended survival rates are extremely low [118–
120]. MSGTs show low sensitivity to chemotherapy and
surgery because of anatomical limitations [121, 122]. Since
radiation is also less eﬀective, novel therapeutic approaches
are eagerly anticipated. Triggering tumor dormancy as a
consequence of hormone therapy would represent a novel
strategy for the treatment of patients with MSGTs.
4. Conclusions
Besides surgical resection and radiation of MSGTs, there are
no other eﬀective therapies. Adjuvant therapy is generally
reserved for palliative treatment; however, there is no clear
evidencethatsuchtreatmentcanbringclinicalbeneﬁts.Since
adverse eﬀects caused by chemotherapy often threaten the
lifeofapatient,andsincesomepatientswithspeciﬁcMSGTs,
especially ACCs, show long survival even with multiple
metastases, the adoption of adjuvant therapy should beInternational Journal of Otolaryngology 5
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Figure 2: Pg suppresses proliferation and invasion of both salivary gland and breast cancer cells. In our recent studies, the inhibitory eﬀect
of Pg on the proliferative and invasive activities of the salivary gland and breast tumor cells was demonstrated, suggesting some common
mechanisms. In both types of cancers, expression of Id-1 and c-myc was downregulated after Pg treatment, whereas p21 expression level was
upregulated.
carefully considered. To achieve new therapeutic methods, it
isnownecessarytoclarifyseveralunansweredquestionssuch
as the expression and/or function of sex steroid hormone
receptors in MSGTs. As indicated by AR expression in SDCs,
there is now evidence linking hormone receptors and growth
factor receptors to the disease. Expression of these receptors
could render the tumors sensitive to hormone therapy.
However, to improve clinical outcome with rather rare
malignancies, more accurate data obtained from multiple
and larger studies are required. MSGTs tend to occur in
older age patients, and triggering tumor dormancy could
be a successful way to slow down their disease progression,
therefore providing an improvement in their quality of
life. Our studies in PR-negative cells also suggest that
the induction of hormone receptor gene expression might
be an option for delaying disease progression. Based on
multiple lines of evidence from a range of cancers, sex
steroid hormone receptors may prove to be appropriate
targets for the establishment of novel treatments for patients
with MSGTs.
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